Skip to main content

Schwaneke Jeffrey A.'s Form 4/A amendment

Amended

agilon health, inc.AGL · filed Apr 3, 2025

Accession no.
0001628280-25-016684
Filed
Apr 3, 2025
Trade date
Nov 29, 2023-Apr 1, 2025
Filing delay
491 days
Rule 10b5-1 plan
Not checked
Original filed
Nov 30, 2023

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $250.2K. It was filed 491 days after the trade.

This amendment replaces 0001628280-23-040361 (filed Nov 30, 2023).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schwaneke Jeffrey A.CIK 0001446919Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 29, 2023Common StockPPurchaseAcquired+22,300$11.22F1+$250,20622,300Indirect
Apr 1, 2025Common StockAGrant or awardAcquired+428,922$0.00$01,130,552Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 1, 2025Common StockAGrant or awardAcquired+673,077$0.00$0673,077Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.12 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was originally reported in November 2023 and is hereby amended to clarify that the shares were purchased by and are held in the Schwaneke Family Joint Spousal Trust.

F3

Restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.

F4

Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.

F5

Includes restricted stock units.

F6

Options that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.

Read the full filing on SEC EDGAR (opens in a new tab)